Case Report

A case of a facial nerve venous malformation presenting with crocodile tear syndrome

Dinesh Rao¹, Peter Fiester¹, Gazanfar Rahmathulla², Rafaat Makary³, Daryoush Tavanaiepour²

Departments of ¹Neuroradiology, ²Neurosurgery, ³Pathology, University of Florida College of Medicine, Jacksonville, Florida, United States.

E-mail: Dinesh Rao - dinesh.rao@jax.ufl.edu; Peter Fiester - peter.fiester@jax.ufl.edu; Gazanfar Rahmathulla - gazanfar.rahmathulla@jax.ufl.edu; Rafaat Makary - rafaat.makary@jax.ufl.edu; Daryoush Tavanaiepour - daryoush.tavanaiepour@jax.ufl.edu

INTRODUCTION

A 39-year-old male presented to the clinic with a complaint of the right hemifacial spasms that progressed to partial facial paralysis. The patient was diagnosed with Bell's palsy and underwent Botox injection with improvement in the spasms. Several months later, he developed partial facial paralysis. The patient was unable to close his eyes and only had lacrimation from the right eye with eating and exercise. On presentation to the neurosurgical service, the patient had a House–Brackmann Grade 4 facial palsy which was noted to be moderate to severe with obvious weakness and disfiguring asymmetry. No other symptoms or relevant history was reported.

The patient underwent both magnetic resonance imaging (MRI) and computed tomography (CT) scan of the brain and temporal bones which demonstrated an enhancing mass lesion in the right petrous bone involving the geniculate ganglion (GG) of the right facial nerve [Figures 1 and 2]. The lesion was expansile, with smooth osseous remodeling. There were no aggressive radiographic features. The lesion was felt to represent either a slow flow venous malformation or a schwannoma of the facial nerve. Due to the close proximity of the lesion to the facial nerve and high risk for facial nerve injury, serial observation was recommended over surgery to the patient. The risks of surgery including complete facial paralysis, hearing loss, and stroke were explained to the patient. In addition, it was made clear that surgery would most likely not result in improved facial function. However, after several months, the patient requested surgery with the hope of improved facial...
nerve function and pathological confirmation. The patient underwent a middle fossa infratemporal craniotomy for biopsy or resection of the lesion [Figure 3]. The patient was placed in supine position with the head turned to the left to expose the right ear. A linear incision overlying the root of the zygoma was made and an extradural dissection to the middle fossa was performed. The lesion was identified with the aid of neuronavigation. There was a bony dehiscence in the location of the lesion, which appeared as a small purple-colored lesion. The lesion was debulked until the facial nerve could be identified. A gross total resection was deemed to be unsafe and would risk a complete facial nerve paralysis. The skull base was then repaired and the wound was closed.

Pathologic examination of the lesion revealed a vascular malformation characterized by a conglomerate of blood vessels of variable caliber ranging from small to large [Figure 4a-d]. The vessel walls were irregular with no obvious elastic lamina, favoring a venous type of vascular malformation.

Immediately after resection, the patient regained some function and was able to lift his eyelid, but his facial palsy returned soon after surgery, with overall Grade 4 House–Brackmann palsy. Several months later, the patient underwent facial reanimation surgery and gold weight placement. He had good results postoperatively, but his facial palsy eventually returned. He was noted to have House–Brackmann Grade 4 facial palsy on follow-up appointments. The patient also reports residual symptoms related to crocodile tears syndrome (CTS).
DISCUSSION

Facial nerve venous malformations (FNVMs) are slow-growing, benign vascular lesions that arise from perineural capillary networks. They may involve any segment of the facial nerve and most commonly involve the GG.

FNVMs were previously described as hemangiomas and initially characterized on CT has have irregular ill-defined margins with intralesional bone spicules in a honeycomb pattern.¹⁵

On MRI, FNVMs are T1 isointense to hypointense, T2 hyperintense relative to adjacent gray matter and avidly enhance.¹⁴,1₁,₁₆,₂₃ Histologically, lesions are characterized by hematoxylin-eosin stains demonstrating dilated vascular spaces lined with endothelial cells that are mitotically quiescent with no internal elastic lamina.²

FNVMs account for <1% of temporal bone lesions and 18% of facial nerve tumors.⁹ The peak incidence of FNVMs occurs between 30 and 60 years of age slightly more common in females.⁶ Most commonly, lesions are reported to be centered on the GG with patients presenting with both progressive and sudden facial paralysis and spasm.¹⁶ Other symptoms include conductive hearing loss, otalgia, pulsatile tinnitus, aural bleeding, and vertigo. Potential explanations for neural injury have included nerve compression, vascular steal, and invasion.⁷

To the best of our knowledge, parasympathetic symptoms related to facial nerve injury have not been reported with FNVM.

CTS, also known as Bogorad syndrome, is characterized by lacrimation caused by olfactory and gustatory stimuli and mastication. The phenomenon is also known as paroxysmal lacrimation or the gustolacrimal reflex.³,⁴ This most often occurs in patients recovering from Bell's palsy. The most widely accepted theory is due to injury to the nervus intermedius either due to Bell's palsy or traumatic injury. The nervus intermedius consists of fibers from the superior salivary nucleus which is located in the medulla. The nervus intermedius contains parasympathetic fibers whose stimulation results in secretion of the lacrimal and submandibular glands. Traveling along these fibers is afferent gustatory sensory fibers from the chorda tympani whose cell bodies reside in the solitary nucleus.

During the recovery from Bell's palsy, the parasympathetic fibers undergo regeneration but are misdirected, with fibers previously destined for salivary glands growing to the ipsilateral lacrimal gland. The regenerating nerves grow along the greater superficial petrosal nerve (GSPN) which results in olfactory or gustatory stimulation causing ipsilateral lacrimation.²⁰ An alternative theory is thought to be the formation of an artificial synapse at the injury site allowing the salivary fibers to jump to the GSPN, leading to lacrimation symptoms.¹³

The incidence of Bell's palsy is 0.08% per year and increases with age.¹² CTS is a relatively uncommon complication of Bell's palsy, occurring in approximately 3.3% of patients with symptoms occurring approximately 6–9 months after the onset of facial paralysis.²¹

Treatment

The most commonly accepted form of treatment of FNVM is surgical excision.¹⁷ Tumors that are extraneural can be safely separated and resected from the nerve.¹⁸ Preservation of facial function is not possible in cases with direct nerve invasion. Small lesions produce less compression of the facial nerve and are more likely to be safely removed while preserving facial nerve function. Larger lesions are more likely to be closely attached to the facial nerve, making it difficult to separate. The nerve may be sacrificed in these cases and reconstructed with an interposition nerve graft.²² Recurrence of FNVM is rare after complete or partial excision.¹⁹

Regarding the clinical management of CTS, different treatment options have been used to stop lacrimation including guanethidine to block adrenergic receptors, propantheline bromide, and homatropine hydrobromide drops; however, the side effects have caused them to fall out of use.¹₂,₂₀

Surgical management, including excision of the palpebral lobe of the lacrimal gland, neurolysis of the chorda tympani or vidian nerve, and sphenopalatine nerve block, have been suggested to treat CTS but may be ineffective due to redundant innervation and come with significant morbidity such as vision loss and loss of taste.

The most commonly used treatment of CTS is Botox injection of the lacrimal gland. Botox is an acetylcholine esterase inhibitor and stops transmission along the aberrant parasympathetic nerves to the affected lacrimal gland.¹₁,₁₄ Botox injection has been shown to cause marked improvement or complete resolution of symptoms, with the treatment effects lasting approximately 6 months. Long-term safety and efficacy, however, has not been established.¹₄

Differential diagnosis

The most common imaging differential diagnosis for an FNVM is a schwannoma. Schwannomas more commonly occur at the internal auditory canal (IAC) and present with hearing loss. Hemangiomas occurring at the GG or IAC are typically smaller and more symptomatic.¹⁵ FNVM and schwannoma have overlapping imaging characteristics with avid enhancement and smooth osseous expansion and...
remodeling of the facial nerve canal and IAC. The presence of intralesional calcification can be used to distinguish FNVMs from facial nerve schwannoma. It has been suggested that the presence of calcification effectively excludes schwannoma from the diagnosis.

**CONCLUSION**

We report a case of CTS in a 39-year-old male who presented with facial paralysis related to a venous malformation involving the GG of the right facial nerve. To the best of our knowledge, this is the first case of CTS reported in literature related to a vascular malformation. The diagnosis of CTS is usually made 6–9 months after the onset of Bell’s palsy and is characterized by lacrimation occurring with olfactory and gustatory stimulation and mastication. The most common treatment option is the injection of Botox directly into the lacrimal gland with relief of symptoms lasting approximately 6 months.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent forms.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Achilli V, Mignosi S. Facial nerve hemangioma. Otol Neurotol 2002;23:1003-4.
2. Benoit MM, North PE, McKenna MJ, Mihm MC, Johnson MM, Cunningham MJ. Facial nerve hemangiomas: Vascular tumors or malformations? Otalaryngol Head Neck Surg 2010;142:108-14.
3. Bogorad FA. The symptom of crocodile tears. F. A. Bogorad. Introduction and translation by austin seckersen. J Hist Med Allied Sci 1979;34:74-9.
4. Friedman O, Neff BA, Wilcox TO, Kenyon LC, Sataloff RT. Temporal bone hemangiomas involving the facial nerve. Otol Neurotol 2002;23:760-6.
5. Glasscock ME 3rd, Smith PG, Schwaber MK, Nissen AJ. Clinical aspects of osseous hemangiomas of the skull base. Laryngoscope 1984;94:869-73.
6. Guerin JB, Takahashi EA, Lane JI, Hoxworth JM, Weindling SM, Blessing MM, et al. Facial nerve venous malformation: A radiologic and histopathologic review of 11 cases. Laryngoscope Investig Otolaryngol 2019;4:347-52.
7. Lahlou G, Nguyen Y, Russo FY, Ferrary E, Sterkers O, Bernardeschi D. Geniculate ganglion tumors: Clinical presentation and surgical results. Otolarngol Head Neck Surg 2016;155:850-5.
8. Lo WW, Horn KL, Carberry JN, Solti-Bohman LG, Wade CT, Brackmann DD, et al. Intratemporal vascular tumors: Evaluation with CT. Radiology 1986;159:181-5.
9. Mangham CA, Carberry JN, Brackmann DE. Management of intratemporal vascular tumors. Laryngoscope 1981;91:867-76.
10. McCoy FJ, Goodman RC. The crocodile tear syndrome. Plast Reconstr Surg 1979;63:58-62.
11. Mijangos SV, Meltzer DE. Case 171: Facial nerve hemangioma. Radiology 2011;260:296-301.
12. Modi P, Arsiwalla T. Crocodile Tears Syndrome. Statpearls: NCBI Bookshelf; 2018.
13. Montoya FJ, Riddell CE, Caesar R, Hague S. Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland. Eye (Lond) 2002;16:705-9.
14. Nava-Castañeda A, Tovilla-Canales JL, Boullosa V, Tovilla-y-Pomar JL, Monroy-Serrano MH, Tapia-Guerra V, et al. Duration of botulinum toxin effect in the treatment of crocodile tears. Ophthalmic Plast Reconstr Surg 2006;22:453-6.
15. Nemet AY, Vinker S. Considerations and complications after Bell’s palsy. J Clin Neurosci 2019;22:1949-53.
16. Oldenburg MS, Carlson ML, Van Abel KM, Driscoll CL, Link MJ. Management of geniculate ganglion hemangiomas: Case series and systematic review of the literature. Otol Neurotol 2015;36:1735-40.
17. Pulec JL. Facial nerve angiomia. Ear Nose Throat J 1996;75:225-38.
18. Sataloff RT, Frattali MA, Myers DL. Intracranial facial neuromas: Total tumor removal with facial nerve preservation: A new surgical technique. Ear Nose Throat J 1995;74:248-56.
19. Semaan MT, Slattery WH, Brackmann DE. Geniculate ganglion hemangiomas: Clinical results and long-term follow-up. Otol Neurotol 2010;31:665-70.
20. Spiers AS. Syndrome of “crocodile tears”: Pharmacological study of a bilateral case. Br J Ophthalmol 1970;54:330-4.
21. Valença MM, Valença LP, Lima MC. Idiopathic facial paralysis (Bell’s palsy): A study of 180 patients. Arq Neuropsiquiatr 2001;59:733-9.
22. Wick CC, Sakai M, Richardson TE, Isaacson B. Transcanal endoscopic ear surgery for excision of a facial nerve venous malformation with interposition nerve grafting: A case report. Otol Neurotol 2017;38:895-9.
23. Yue Y, Jin Y, Yang B, Yuan H, Li J, Wang Z. Retrospective case series of the imaging findings of facial nerve hemangioma. Eur Arch Otorhinolaryngol 2015;272:2497-503.

How to cite this article: Rao D, Fiester P, Rahmathulla G, Makary R, Tavanaiepour D. A case of a facial nerve venous malformation presenting with crocodile tear syndrome. Surg Neurol Int 2020;11:3.